Gabriella Ferrandina
Overview
Explore the profile of Gabriella Ferrandina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
312
Citations
4371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Macchia G, Pezzulla D, Ferrandina G, Deodato F
Int J Radiat Oncol Biol Phys
. 2025 Mar;
121(5):1401-1402.
PMID: 40089346
No abstract available.
2.
Macchia G, Pezzulla D, Russo D, Campitelli M, Lucci S, Fanelli M, et al.
Anticancer Drugs
. 2025 Jan;
36(3):238-245.
PMID: 39784120
The aim of this study was to present a nationwide survey on the specialist's attitudes towards stereotactic body radiotherapy (SBRT) combined with poly (ADP-ribose) polymerase inhibitors (PARPi) with oligometastatic/oligoprogressive/oligorecurrent ovarian...
3.
Masi I, Ottavi F, Rio D, Caprara V, Vastarelli C, Giannitelli S, et al.
Cell Death Dis
. 2024 Oct;
15(10):766.
PMID: 39433739
No abstract available.
4.
Macchia G, Campitelli M, Pezzulla D, Lucci S, Fodor A, Russo D, et al.
Int J Radiat Oncol Biol Phys
. 2024 Sep;
121(3):693-702.
PMID: 39326506
Purpose: MITO-RT3/RAD (NCT04593381) is a prospective multicenter phase 2 trial designed to assess the effectiveness and safety of stereotactic body radiation therapy (SBRT) in patients who received diagnoses of oligometastatic...
5.
Macchia G, Pezzulla D, Campitelli M, Russo D, Ronzino G, Lucci S, et al.
Int J Radiat Oncol Biol Phys
. 2024 Sep;
121(2):465-474.
PMID: 39255875
Purpose: The aim of this observational, retrospective, multicenter study (Epimetheo) was to analyze the activity and the safety of stereotactic body radiation therapy (SBRT) during poly(ADP-ribose)-polymerase inhibitor (PARPi) maintenance in...
6.
Bizzarri N, Pedone Anchora L, Teodorico E, Certelli C, Galati G, Carbone V, et al.
Eur J Surg Oncol
. 2024 Aug;
50(12):108645.
PMID: 39214031
Objective: Peritoneal involvement may be overlooked in patients with locally advanced cervical cancer (LACC). This may lead to underestimation of prognosis and to undertreatment limited to locoregional disease locations. However,...
7.
Ciccarone F, Biscione A, Robba E, Pasciuto T, Giannarelli D, Gui B, et al.
Am J Obstet Gynecol
. 2024 Jul;
232(1):108.e1-108.e22.
PMID: 39084498
Background: Differential diagnosis between benign uterine smooth muscle tumors and malignant counterpart is challenging. Objective: To evaluate the accuracy of a clinical and ultrasound based algorithm in predicting mesenchymal uterine...
8.
Sassu C, Marchetti C, Russo G, Minucci A, Boccia S, Benato A, et al.
Int J Gynecol Cancer
. 2024 May;
34(1):88-98.
PMID: 38805344
Objective: To evaluate disease characteristics and survival according to status, administration of poly-(ADP-ribose) polymerase inhibitors (PARPi), and surgery in patients with ovarian cancer and brain metastases. Methods: This is a...
9.
Rosati A, Certelli C, Ferrandina G, Fanfani F, Scambia G, Gallotta V
Int J Gynecol Cancer
. 2024 Apr;
34(9):1472-1473.
PMID: 38649233
No abstract available.
10.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, et al.
Eur J Cancer
. 2024 Apr;
203:114039.
PMID: 38598922
Background: cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy in advanced cervical cancer (CC) patients treated with...